| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer
1 company
Tamer I Khayal last filed a Form 4 in March 2025, as Chief Commercial Officer at TMDX. Tamer I Khayal's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Tamer I Khayal's trades have earned a middling insider score of 53/100 across 47 rated trades. Over a 12-month horizon, 46.8% of those trades were profitable, with an average 12-month return of -14.3%.
At the last filing, the largest reported position was 36,042 shares of TMDX. The TMDX filings lean toward selling, a net 402,101 shares.
Tamer I Khayal has 52 Form 4 filings on record from May 2019 to March 2025, all as Chief Commercial Officer at TransMedics Group (TMDX), 2019–2025.
The 217 reported transactions were 127 open-market sales, 71 option exercises, 10 other transactions and 6 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 43 sales worth about $30.3M.
The largest open-market sale was 78,036 shares of TMDX at an average $109.78 on May 1, 2024, about $8.6M. Twelve months later TMDX was down 23%.
20 of the 24 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 4 were not.
Shares as reported in the last Form 4 for each company; the most recent is from March 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 3, 2025 | TMDX Transmedics Group, Inc. | Chief Commercial Officer | Sell | 2,407 | $76.43 | $183,967.01 | -6.3% | +78.8% | +113.5% | |
| Jan 7, 2025 | TMDX Transmedics Group, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 1,083 | $80.05 | $86,694.15 | -4.9% | -12.1% | +74.5% | |
| Dec 2, 2024 | TMDX Transmedics Group, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 1,084 | $86.40 | $93,657.60 | -4.9% | -18.6% | +66.5% | |
| Nov 11, 2024 | TMDX Transmedics Group, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 1,458 | $90.04 | $131,278.32 | -6.5% | -21.2% | +37.1% | |
| Nov 1, 2024 | TMDX Transmedics Group, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 1,083 | $82.64 | $89,499.12 | -4.9% | -18.8% | +59.6% | |
| Oct 1, 2024 | TMDX Transmedics Group, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 2,958 | $148.24 | $438,490.90 | -12.4% | -59.1% | -20.7% | |
| Sep 3, 2024 | TMDX Transmedics Group, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 2,960 | $159.60 | $472,403.54 | -12.4% | -46.6% | -32.9% | |
| Aug 1, 2024 | TMDX Transmedics Group, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 2,958 | $156.77 | $463,727.17 | -12.4% | -45.9% | -20.4% | |
| Jul 1, 2024 | TMDX Transmedics Group, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 2,958 | $151.40 | $447,852.94 | -12.4% | +4.5% | -13.4% | |
| Jun 3, 2024 | TMDX Transmedics Group, Inc. | Chief Commercial Officer | Sale+OE10b5-1 | 2,960 | $133.10 | $393,985.95 | -12.4% | +19.3% | -3.7% |